


Accepted Manuscript

JCL Roundtable: Future of the Lipid Laboratory: Using the Laboratory to Manage the Patient (Part 2)

W. Virgil Brown, MD, Yehuda Handelsman, MD, Seth S. Martin, MD, Pamela B. Morris, MD



PII: S1933-2874(17)30328-8

DOI: [10.1016/j.jacl.2017.05.002](https://doi.org/10.1016/j.jacl.2017.05.002)

Reference: JACL 1114

To appear in: *Journal of Clinical Lipidology*

Received Date: 10 May 2017

Accepted Date: 11 May 2017

Please cite this article as: Brown WV, Handelsman Y, Martin SS, Morris PB, JCL Roundtable: Future of the Lipid Laboratory: Using the Laboratory to Manage the Patient (Part 2), *Journal of Clinical Lipidology* (2017), doi: 10.1016/j.jacl.2017.05.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

JCL Roundtable: Future of the Lipid Laboratory: Using the Laboratory to Manage the Patient (Part 2)

W. Virgil Brown, MD*; Yehuda Handelsman, MD; Seth S. Martin, MD; Pamela B. Morris, MD

Emory University School of Medicine, 3208 Habersham Rd., NW, Atlanta, GA 30305, USA (Dr. Virgil Brown); Metabolic Institute of America, 18372 Clark Street, Ste. 212, Tarzana, CA 91356, USA (Dr. Yehuda Handelsman); Johns Hopkins School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA (Dr. Seth Martin); Medical University of South Carolina, 171 Ashley Ave., Charleston, SC 29425, USA (Dr. Pamela Morris)

Keywords:

Cholesterol
Triglycerides
Metabolic disorders
Metabolism
Lipoprotein

Abstract: The measurement of cholesterol and triglycerides as indicators of metabolic disorders and most particularly of vascular disease risk has been of growing importance to physicians and epidemiologists over the past century. This was refocused on the lipoproteins, the specific packages in blood that carry these lipids, by John Gofman, MD, PhD, and Don Fredrickson, MD, more than 50 years ago. We continue to learn about the metabolism of these large molecular structures and their relationship to arteriosclerosis as new genetic and interventional studies are published. The clinical laboratory has evolved to provide more focused information with measures that can help us assess risk and target our therapy more effectively. In this Roundtable discussion, I had the opportunity to talk with physicians who consider lipoprotein management to be central features of their practice every day. They personally care for patients with metabolic disorders in which the lipoproteins have caused disease or are predicted to do so. They are well-versed on the way that science is leading us in our field. I believe that you will learn from their view of current needs regarding lipoprotein measures and the changes that may derive from ongoing scientific studies in our field.

*Corresponding author

Email address: wbrow925@bellsouth.net

This roundtable was supported by an educational grant from Quest Diagnostics

Download English Version:

<https://daneshyari.com/en/article/5615223>

Download Persian Version:

<https://daneshyari.com/article/5615223>

[Daneshyari.com](https://daneshyari.com)